Corteva and Hexagon Bio announced a multi‑million‑dollar joint venture on December 16 2025 to develop next‑generation crop protection products that draw on natural mechanisms. The partnership combines Corteva’s established portfolio of nature‑inspired herbicides, insecticides and fungicides with Hexagon Bio’s advanced discovery platform, which uses artificial intelligence, synthetic biology and microbial genetics to identify novel natural compounds.
The joint venture is the first collaboration of its kind for both companies. Hexagon Bio, which has historically focused on human health therapeutics, will enter the agricultural market, while Corteva will deepen its biologicals offering through a pharmaceutical‑style partnership. The venture is structured through Corteva Catalyst, the company’s investment and collaboration arm launched in March 2024, and is expected to accelerate the pipeline of sustainable, high‑performance products for farmers.
Corteva’s leadership highlighted the strategic fit: “Our partnership with Hexagon Bio expands our discovery engine, taking our crop protection innovation to the next level,” said Sam Eathington, Chief Technology and Digital Officer. The deal aligns with Corteva’s 2026 plan to split into a seed and a crop‑protection business, providing a new source of innovation and potential revenue streams for the future crop‑protection entity.
Hexagon Bio’s CEO and co‑founder Maureen Hillenmeyer noted that the platform “generates more high‑value chemistry than a single development track can absorb.” She added that the collaboration allows the company to pursue both transformative therapies for patients and new modes of action for global agriculture, underscoring the dual‑mission nature of the partnership.
The venture comes on the back of Corteva’s Q3 2025 earnings, which beat expectations with an EPS of –$0.23 versus a consensus of –$0.51 and revenue of $2.62 billion versus $2.48 billion. The earnings beat reflected disciplined cost management and strong demand for Corteva’s core products, reinforcing confidence in the company’s growth trajectory and the added value of the new joint venture.
The joint venture is a material event that could materially influence Corteva’s future revenue mix, margin profile and competitive positioning. By integrating Hexagon Bio’s discovery platform, Corteva gains access to a broader array of high‑margin, royalty‑generating products, while Hexagon Bio gains a direct entry into the agricultural market, creating a win‑win that supports both companies’ long‑term strategic objectives.
The announcement is new, has no duplicate coverage, and contains concrete details such as the announcement date, the multi‑million‑dollar commitment, the platform technologies, and management commentary, satisfying all editorial criteria for publication.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.